Drug Trial Radar · NCT02625389
A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embolization Procedures
Last checked: Nov 20, 2026Latest source record: Oct 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
132
Actual
Start
Nov 29, 2017
Primary completion
May 12, 2021
Study completion May 12, 2021
Sponsor
- Lead sponsor
- GuerbetIndustry
- Sponsor type
- Industry
- First posted
- Dec 9, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a multicenter phase IV Post-Marketing Study. The study is designed to investigate the safety of Lipiodol® Ultra Fluid in association with surgical glues used according to each site medical practice of vascular embolization. Subjects will be enrolled with the main condition that a procedure of vascular embolization using Lipiodol® Ultra Fluid in association with surgical glues is part of their therapeutic/palliative strategy for their disease. The vascular embolization using Lipiodol® Ultra Fluid in association with surgical glue will be administered as study procedure. According to the patient need and health status a second vascular embolization using Lipiodol® Ultra Fluid in association with surgical glue may be considered by the investigator within the next 30 days after the first one. In this case, this procedure will be considered as a second study procedure. The per-procedure safety evaluation will be enabled by appropriate records of safety events during the time frame of the procedure of vascular embolization using Lipiodol® Ultra Fluid in association with surgical glues. Safety evaluation will be completed with safety records within 30 +/-3 days after the embolization procedure. Efficacy evaluation will rely on the level of lesion(s) obliteration after embolization compared to the pre-procedural target level of obliteration. Exploratory descriptive statistical methods will be used to evaluate safety and efficacy, using both the total population and subsets of subjects with similar clinical conditions.
Conditions
- Congenital Hemangioma
- Hemangioendothelioma
- Angiosarcoma
- Arteriovenous Malformations
Interventions
Lipiodol Ultra Fluid with surgical gluesDrug
Lipiodol Ultra Fluid and surgical glue mixture administered via selective arterial catheterization.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Drug Reactions During the Embolization ProcedureTime frame: Collected between administration of the mixture and catheterization laboratory discharge (up to 1 day)
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
KLES Dr. Prabhakar Kore Hospital
Belagavi, India
Victoria Hospital
Bengaluru, India
Mazumdar Shaw medical Centre
Bengaluru, India
Mahatma Gandhi Missions Medical college and Hospital
Chhatrapati Sambhajinagar, India
Apollo Hospital
Hyderabad, India
AIIMS
Jodhpur, India
Sanjay Gandhi Post Graduate Institute of Meducal Sciences (SGPGI)
Lucknow, India
Government Medical College
Nagpur, India
BLK Super Speciality Hospital
New Delhi, India
AIIMS
New Delhi, India
B.J Govt College & Sassoon Hospitals
Pune, India
KEM Hospital
Pune, India
7 Orange Hospitals
Pune, India
Geetanjali Medical College and Hospital
Udaipur, India
Acharya Vinobha Bhave Hospital
Wardha, India
Division of Peripheral Vascular & Endovascular sciences, Medanta-The Medicity Hospital
Gurgaon, Haryana, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.